Homology Medicines Inc (NASDAQ:FIXX) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 3,618,500 shares, an increase of 13.5% from the July 31st total of 3,188,800 shares. Based on an average daily volume of 274,600 shares, the days-to-cover ratio is currently 13.2 days. Currently, 12.9% of the shares of the company are short sold.

In other news, insider Albert Seymour sold 9,300 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $18.98, for a total transaction of $176,514.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Siyamak Rasty sold 8,000 shares of the business’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $20.00, for a total transaction of $160,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 92,566 shares of company stock worth $1,714,997. 33.40% of the stock is currently owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in FIXX. Price T Rowe Associates Inc. MD boosted its holdings in Homology Medicines by 84.3% during the second quarter. Price T Rowe Associates Inc. MD now owns 1,957,184 shares of the company’s stock worth $38,302,000 after buying an additional 894,960 shares in the last quarter. BlackRock Inc. boosted its holdings in Homology Medicines by 48.7% during the second quarter. BlackRock Inc. now owns 2,084,139 shares of the company’s stock worth $40,786,000 after buying an additional 682,665 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Homology Medicines by 53.9% during the second quarter. Vanguard Group Inc. now owns 1,016,124 shares of the company’s stock worth $19,886,000 after buying an additional 355,908 shares in the last quarter. Cormorant Asset Management LP purchased a new stake in Homology Medicines during the second quarter worth about $5,871,000. Finally, Point72 Asset Management L.P. purchased a new stake in Homology Medicines during the second quarter worth about $3,996,000. 68.09% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts have recently issued reports on FIXX shares. Robert W. Baird started coverage on shares of Homology Medicines in a research note on Monday. They set an “outperform” rating and a $30.00 price target on the stock. Canaccord Genuity set a $37.00 price target on shares of Homology Medicines and gave the stock a “buy” rating in a research note on Friday, July 26th. HC Wainwright set a $36.00 price target on shares of Homology Medicines and gave the stock a “buy” rating in a research note on Tuesday, June 11th. Finally, Zacks Investment Research upgraded shares of Homology Medicines from a “sell” rating to a “hold” rating in a research note on Tuesday, July 16th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $31.40.

FIXX stock traded down $0.10 during trading on Friday, reaching $20.38. 4,005 shares of the company were exchanged, compared to its average volume of 244,810. The company has a market cap of $954.07 million, a P/E ratio of -10.10 and a beta of 0.11. Homology Medicines has a 52-week low of $14.19 and a 52-week high of $31.80. The stock’s 50 day moving average price is $18.02 and its 200 day moving average price is $21.60.

Homology Medicines (NASDAQ:FIXX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.06). The company had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $1.00 million. Homology Medicines had a negative return on equity of 38.74% and a negative net margin of 3,232.67%. Equities analysts expect that Homology Medicines will post -2.27 earnings per share for the current fiscal year.

About Homology Medicines

Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

See Also: What is a balanced fund?

Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.